脂质代谢紊乱和骨质疏松  

Lipid metabolism disorders and osteoporosis

作　　者：厉婷[1] 崔燎[1] 

机构地区：[1]广东医学院药理教研室,湛江524023

出　　处：《中国骨质疏松杂志》2008年第6期428-432,共5页Chinese Journal of Osteoporosis

摘　　要：骨质疏松或骨量减少与脂质代谢紊乱常并存,它们之间的关系日益受到研究者的关注。现在研究提示,过氧化物酶体增殖物激活受体γ(PPARγ)等因子有可能在两者的发病机制中起到关键作用,并且脂质代谢紊乱导致的骨髓脂肪增多可能是导致骨髓微循环障碍和骨量减少的主要原因。能够同时纠正脂质代谢紊乱和防治骨质疏松的药物是目前药理学研究的热点之一。笔者就脂质代谢紊乱和骨质疏松的关系进行简要综述。More and more people pay close attention to the relationship between osteoporosis or osteopenia and lipid metabolism disorders,because they are intercurrent.Recently,research shows that peroxisome proliferators-activated receptorγ（PPARγ） maybe take key role in osteoporosis or ostepenia and lipid metabolism disorders.Bone marrow fat cell caused by lipid metabolism disorders may be the important material with respect to bone marrow microcirculation and osteopenia.It is one of hot spots in pharmacology that drug can rectify lipid metabolism disorders and prevention and cure osteoporosis together.

关 键 词：脂质代谢 骨质疏松 过氧化物酶体增殖物激活受体Γ 骨髓微循环 

分 类 号：R589.2[医药卫生—内分泌] R681[医药卫生—内科学]